Eris Lifesciences Ltd.
ERIS · NSE · Healthcare
With a 20% margin of safety, our buy-below price is ₹1,640.29.
Piotroski F-score 5/9 — quality of earnings & balance sheet.
Investability checklist
- ✓ROE above 15%18.1%
- ✕Low debt (D/E < 0.5)0.61x
- ✕Positive free cash flow
- ✕Revenue growth > 10%7%
- ✓Earnings growing200%
- ✓Net margin ≥ 10%19.9%
- ✕Current ratio > 1.50.74
- ✓Below our fair value
- ✓Margin of safety ≥ 20%
- ✕Above 200-day average
- ✓Above 50-day average
- –Positive 1-year return
- ✓Altman Z in safe zoneZ 4.19
- ✕Piotroski ≥ 75/9
1-year price
EOD · 2026-06-15Our scores
Key fundamentals
SWOT snapshot
Strengths
- •Strong return on equity (18.1%).
- •Healthy profit margin (19.9%).
- •Financially solid — Altman Z 4.19.
Weaknesses
- •Price below its 200-day moving average (downtrend).
Opportunities
- •Earnings growing (200% YoY).
- •Trading in our value buy zone versus sector peers.
- •Trades ~48% below our estimated fair value.
About Eris Lifesciences Ltd.
Eris Lifesciences Limited, together with its subsidiaries, provides domestic branded formulations for chronic and sub-chronic therapies in India and internationally. The company offers various branded formulations in various therapeutic areas, such as antidiabetes, cardiovascular, nutrition, dermatology, neuroscience, gynecology, nephrology, and oncology, as well as central nervous system, women's health, and vitamins/minerals/nutrients. It also provides patient care service
More in Healthcare
Our verdict, fair value, financial-health and checklist are StocksWizard's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.